AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment
AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates.
Why it matters: The partnership gives AstraZeneca a route to combine its tumor-targeting drugs with a closely watched next-generation immunotherapy. Summit gains funding and a major development partner while retaining its rights to ivonescimab.
Zoom in: AstraZeneca’s investment will give it a stake equivalent to about 12% of Summit’s outstanding common stock, or 10.6% on a fully diluted basis.
- The first collaboration will pair ivonescimab with sonesitatug vedotin, known as Sone-Ve, in gastrointestinal cancers. Both companies will supply their medicines and share trial costs. Each retains development and commercial rights to its own drug.
- A broader collaboration covering additional AstraZeneca cancer medicines remains subject to a nonbinding memorandum of understanding.
How it works: Ivonescimab, developed by China’s Akeso and licensed to Summit in territories including Europe and the U.S., blocks two targets. Blocking PD-1 helps immune cells attack cancer; blocking VEGF inhibits the formation of blood vessels that support tumor growth.
- Sone-Ve targets the protein claudin-18.2 to deliver a cell-killing payload. The combination would bring targeted tumor killing, immune activation and blood-vessel inhibition into one treatment regimen.
The big picture: Enthusiasm for ivonescimab grew after a China-only Phase 3 lung cancer trial showed it halved the risk of disease progression or death compared with Merck’s Keytruda. The findings helped trigger a wave of deals around drugs targeting PD-1 and VEGF.
Yes, but: That result does not establish superiority over Keytruda-based treatment globally. Summit’s multiregional HARMONi-3 trial is currently testing ivonescimab plus chemotherapy against Keytruda plus chemotherapy as an initial treatment for metastatic non-small cell lung cancer.
- The proposed ADC combinations also need clinical validation. Sone-Ve recently improved overall survival in a Phase 3 gastric cancer trial, although its progression-free survival endpoint did not reach statistical significance.
What’s next: The companies plan to start gastrointestinal cancer combination studies shortly. Separately, the FDA is due to decide by Nov. 14 whether to approve ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose disease progressed after targeted treatment.
